唑来膦酸治疗绝经后骨质疏松症临床疗效的研究

发布时间：2018-06-19 17:06

  本文选题：绝经后骨质疏松症 + 唑来膦酸　； 参考：《浙江大学》2017年硕士论文

【摘要】：目的:研究分析使用唑来膦酸治疗66例绝经后女性骨质疏松症患者的临床疗效。方法:选择2012-2016年间在我院骨科住院行静脉滴注唑来膦酸治疗的绝经后女性骨质疏松症患者共66例,年龄范围51-97岁,平均(68.606±8.621)岁。患者使用唑来膦酸(密固达)5mg(100ml)静脉滴注1次,滴注时间15min以上,并且患者每天基础服用骨矿化促进药物骨化三醇0.5μg/d及碳酸钙片1片/天。在使用唑来膦酸治疗前、治疗1年后分别检测患者腰椎总骨密度、右侧髋关节骨密度,以及血清总Ⅰ型胶原氨基酸延长肽(t-P11NP)、N端骨钙素(N-MID)、β-胶原特殊序列(β-CTX)、25-羟基维生素D(25-OH-VD)这些骨代谢指标,并对检测结果进行统计分析。比较患者骨密度、血清骨代谢指标在治疗前后的变化差异,以及在各年龄段(51-60岁,61-70岁,70岁以上)治疗前后的差异。□□结果:患者腰椎总骨密度、血清总Ⅰ型胶原氨基酸延长肽、N端骨钙素、β-胶原特殊序列、25-羟基维生素D在治疗1年后与治疗前相比有显著差异(P0.05)。全髋关节骨密度在治疗1年后与治疗前比较,虽有所增加,但差异却无统计学意义(P0.05)。51-60岁,61-70岁,70岁以上三个年龄分组中腰椎总骨密度、血清总Ⅰ型胶原氨基酸延长肽、N端骨钙素、β-胶原特殊序列、25-羟基维生素D在治疗1年后与治疗前相比均有显著差异(P0.05)。而右氈关节骨密度与治疗前比较虽均有增加,但差异无统计学意义(P0.05)。结论:静脉滴注唑来膦酸治疗绝经后女性骨质疏松症,不仅能有效提高患者腰椎的总骨密度,同时也可改善患者的血清中骨代谢指标,并且对各年龄段的绝经后骨质疏松症女性均有明确的临床效果。
[Abstract]:Objective: to study the clinical effect of zoledronic acid on 66 postmenopausal women with osteoporosis. Methods: a total of 66 postmenopausal female osteoporosis patients, aged 51-97 years, with an average of 68.606 卤8.621 years, were selected from 2012 to 2016. The patients were given zoledronic acid (5 mg / 100 ml) intravenously for more than 15min, and the patients were given bone mineralization promoting drug ossification 0.5 渭 g / d and calcium carbonate tablet 1 / day. The total bone mineral density (BMD) of lumbar vertebrae and the bone density of right hip joint were measured before and 1 year after treatment with zoledronic acid. Serum total type I collagen amino acid prolongation peptide (t-P11NPN), N-terminal osteocalcin N-MIDD, 尾 -collagen special sequence (尾 -CTX, 25-hydroxyvitamin D, 25-OH-VD), and the results were analyzed statistically. To compare the changes of bone mineral density (BMD), serum bone metabolism index (BMD) before and after treatment, and the difference before and after treatment (51-60 years old or 61-70 years old or over) before and after treatment. Results: total bone mineral density of lumbar vertebrae, The serum total type I collagen amino acid prolongation peptide N-terminal osteocalcin, 尾 -collagen special sequence 25 hydroxyvitamin D had significant difference after 1 year compared with that before treatment (P 0.05). The bone mineral density of total hip joint increased a year after treatment compared with that before treatment, but there was no significant difference in total lumbar bone mineral density (BMD) of lumbar vertebrae in three age groups of 61-70 years old and over 70 years old, but the difference was not statistically significant. Serum total type I collagen amino acid prolongation peptide N-terminal osteocalcin and 尾 -collagen special sequence 25-hydroxyvitamin D were significantly different after 1 year treatment compared with those before treatment (P 0.05). The bone mineral density (BMD) of right tapetum was higher than that before treatment, but the difference was not statistically significant (P 0.05). Conclusion: intravenous infusion of zoledronic acid in the treatment of postmenopausal female osteoporosis can not only improve the total bone mineral density of lumbar vertebrae, but also improve the bone metabolism index in serum. And there is a clear clinical effect for postmenopausal osteoporosis women of all ages.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R580
，

本文编号：2040601